Predict your next investment

Holding Company

See what CB Insights has to offer

Investments

1

Portfolio Exits

1

About H7 Holdings

H7 Holdings is a holding company.

H7 Holdings Headquarter Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest H7 Holdings News

Candel Therapeutics Completes $22.5M Series C Funding

Apr 1, 2019

Advantagene, Inc. d.b.a. Candel Therapeutics , an Auburndale, MA-based company developing proprietary immuno-oncology platforms, closed a $22.5m Series C financing. The round was led by Northpond Ventures with participation from Sands Capital Ventures, H7 Holdings and Level One Partners. In conjunction of the financing, Michael P. Rubin, M.D., Ph.D., founder and CEO of Northpond Ventures, will join Candel Therapeutics’s board of directors. The company plans to use the funds to expand its operational capabilities and further accelerate its ongoing clinical development initiatives and to launch a GMCI pivotal trial for brain cancer patients. Led by Dr. Estuardo Aguilar-Cordova, Chairman and CEO, Candel Therapeutics is developing the Gene Mediated Cytotoxic Immunotherapy (GMCI™) and the oncolytic rQNestin34.5 platforms for the treatment of solid tumors. The company’s lead programs are based on the company’s Gene Mediated Cytotoxic Immunotherapy (GMCI™) technology and include two randomized studies in prostate cancer, including a Phase 3 under an FDA approved Special Protocol Assessment. Candel also has ongoing clinical programs in glioma, lung and pancreatic cancer. The company has completed a Phase 2 clinical study in high grade glioma that showed promising results, including an indication of survival benefit. The launch of a combination GMCI-checkpoint inhibitor clinical study, in collaboration with Bristol-Myers Squibb and the Adult Brain Tumor Consortium, was recently announced. Candel also has an ongoing study for recurrent GBM patients with rQNestin34.5, the company’s oncolytic herpes-based platform. FinSMEs

H7 Holdings Investments

1 Investments

H7 Holdings has made 1 investments. Their latest investment was in Candel Therapeutics as part of their Series C on April 4, 2019.

CBI Logo

H7 Holdings Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/1/2019

Series C

Candel Therapeutics

$22.5M

Yes

3

Date

4/1/2019

Round

Series C

Company

Candel Therapeutics

Amount

$22.5M

New?

Yes

Co-Investors

Sources

3

H7 Holdings Portfolio Exits

1 Portfolio Exit

H7 Holdings has 1 portfolio exit. Their latest portfolio exit was Candel Therapeutics on July 27, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/27/2021

IPO

$99M

9

Date

7/27/2021

Exit

IPO

Companies

Valuation

$99M

Acquirer

Sources

9

H7 Holdings Team

1 Team Member

H7 Holdings has 1 team member, including current President, Chief Operating Officer, Barry Simon.

Name

Work History

Title

Status

Barry Simon

President, Chief Operating Officer

Current

Name

Barry Simon

Work History

Title

President, Chief Operating Officer

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.